Financials data is unavailable for this security.
View more
Year on year Vaishali Pharma Ltd 's net income fell -89.11% from 66.04m to 7.19m despite revenues that grew 23.85% from 696.63m to 862.80m. An increase in the selling, general and administrative costs as a percentage of sales from 2.99% to 12.33% was a component in the falling net income despite rising revenues.
| Gross margin | 13.14% |
|---|---|
| Net profit margin | 0.91% |
| Operating margin | 0.73% |
| Return on assets | -- |
|---|---|
| Return on equity | -- |
| Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Vaishali Pharma Ltd increased its cash reserves by 60.28%, or 5.94m. Cash Flow from Investing totalled 12.03m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 8.07m in cash from operations while cash used for financing totalled 14.16m.
| Cash flow per share | 1.18 |
|---|---|
| Price/Cash flow per share | 175.62 |
| Book value per share | -- |
|---|---|
| Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
| Current ratio | -- |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in earnings per share excluding extraordinary items dropped -88.54%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
| EPS growth(5 years) | 0.0163 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -93.32 |
